{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T23:21:06Z","timestamp":1783725666578,"version":"3.55.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":35,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100020595","name":"National Science and Technology Council","doi-asserted-by":"publisher","award":["NSTC 114-2314-B-002-077"],"award-info":[{"award-number":["NSTC 114-2314-B-002-077"]}],"id":[{"id":"10.13039\/100020595","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["115-S0178"],"award-info":[{"award-number":["115-S0178"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["114-X0014"],"award-info":[{"award-number":["114-X0014"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["113-S0099"],"award-info":[{"award-number":["113-S0099"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["NTUH 105-03"],"award-info":[{"award-number":["NTUH 105-03"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005762","name":"National Taiwan University Hospital","doi-asserted-by":"publisher","award":["110-S4878"],"award-info":[{"award-number":["110-S4878"]}],"id":[{"id":"10.13039\/501100005762","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","neurotherapeuticsjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurotherapeutics"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.neurot.2026.e00926","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T09:27:18Z","timestamp":1779182838000},"page":"e00926","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Genotype and subependymal lesion burden influence volumetric response to everolimus in tuberous sclerosis complex-associated subependymal giant cell astrocytoma: A 10-year real-world study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4097-5988","authenticated-orcid":false,"given":"Tzu-Hsuan","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Shinn-Forng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei-Lung","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shih-Hung","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Fai","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6974-971X","authenticated-orcid":false,"given":"Pi-Chuan","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.neurot.2026.e00926_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12030956","article-title":"Subependymal giant cell astrocytomas in tuberous sclerosis complex-current views on their pathogenesis and management","volume":"12","author":"Gao","year":"2023","journal-title":"J Clin Med"},{"key":"10.1016\/j.neurot.2026.e00926_bib2","doi-asserted-by":"crossref","DOI":"10.1038\/nrdp.2016.35","article-title":"Tuberous sclerosis complex","volume":"2","author":"Henske","year":"2016","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00926_bib3","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.pediatrneurol.2013.08.001","article-title":"Tuberous sclerosis complex diagnostic criteria update: recommendations of the 2012 iinternational Tuberous sclerosis complex consensus conference","volume":"49","author":"Northrup","year":"2013","journal-title":"Pediatr Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00926_bib4","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.pediatrneurol.2013.08.017","article-title":"Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the international Tuberous sclerosis complex consensus conference 2012","volume":"49","author":"Roth","year":"2013","journal-title":"Pediatr Neurol"},{"issue":"11","key":"10.1016\/j.neurot.2026.e00926_bib5","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1136\/adc.2011.211995","article-title":"The tuberous sclerosis 2000 study: presentation, initial assessments and implications for diagnosis and management","volume":"96","author":"Yates","year":"2011","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.neurot.2026.e00926_bib6","doi-asserted-by":"crossref","first-page":"705","DOI":"10.3389\/fneur.2019.00705","article-title":"Clinical characteristics of subependymal giant cell astrocytoma in Tuberous sclerosis complex","volume":"10","author":"Jansen","year":"2019","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00926_bib7","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1468-1331.2009.02567.x","article-title":"Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature","volume":"16","author":"Adriaensen","year":"2009","journal-title":"Eur J Neurol"},{"issue":"Pt A","key":"10.1016\/j.neurot.2026.e00926_bib8","article-title":"Mortality in Tuberous sclerosis complex","volume":"121","author":"Parthasarathy","year":"2021","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00926_bib9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.pediatrneurol.2013.12.004","article-title":"Surgical treatment of subependymal giant cell astrocytoma in Tuberous sclerosis complex patients","volume":"50","author":"Kotulska","year":"2014","journal-title":"Pediatr Neurol"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00926_bib10","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/BF00706748","article-title":"Subependymal giant-cell astrocytoma associated with tuberous sclerosis. Do subependymal nodules grow?","volume":"5","author":"Fujiwara","year":"1989","journal-title":"Childs Nerv Syst"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00926_bib11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ejpn.2012.12.008","article-title":"Management of subependymal giant cell astrocytoma (SEGA) associated with tuberous sclerosis complex (TSC): clinical recommendations","volume":"17","author":"Jozwiak","year":"2013","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.neurot.2026.e00926_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106884","article-title":"Paradigm shift in the treatment of tuberous sclerosis: effectiveness of everolimus","volume":"195","author":"Previtali","year":"2023","journal-title":"Pharmacol Res"},{"issue":"9861","key":"10.1016\/j.neurot.2026.e00926_bib13","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0140-6736(12)61134-9","article-title":"Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with Tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"381","author":"Franz","year":"2013","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.neurot.2026.e00926_bib14","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.neurot.2026.e00926_bib15","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.pediatrneurol.2025.04.007","article-title":"Long-term efficacy and safety of mammalian target of rapamycin inhibitor treatment for subependymal giant cell astrocytoma in tuberous sclerosis","volume":"168","author":"Becker","year":"2025","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.neurot.2026.e00926_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pediatrneurol.2025.02.003","article-title":"Clinical manifestations and treatments of patients with tuberous sclerosis with subependymal giant cell astrocytoma","volume":"166","author":"Kim","year":"2025","journal-title":"Pediatr Neurol"},{"issue":"4","key":"10.1016\/j.neurot.2026.e00926_bib17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/pbc.25368","article-title":"Factors affecting response to everolimus therapy for subependymal giant cell astrocytomas associated with tuberous sclerosis","volume":"62","author":"Trelinska","year":"2015","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00926_bib18","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26347","article-title":"Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis (the EMINENTS study)","volume":"64","author":"Trelinska","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00926_bib19","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00381-015-2947-4","article-title":"Association between the growth rate of subependymal giant cell astrocytoma and age in patients with Tuberous sclerosis complex","volume":"32","author":"Tsai","year":"2016","journal-title":"Childs Nerv Syst"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00926_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158476","article-title":"Long-term use of everolimus in patients with Tuberous sclerosis complex: final results from the EXIST-1 study","volume":"11","author":"Franz","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.neurot.2026.e00926_bib21","series-title":"Common terminology criteria for adverse events, (CTCAE), version 5.0 November 27","author":"Institute","year":"2017"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00926_bib22","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/ana.24523","article-title":"Everolimus for subependymal giant cell astrocytoma: 5-year final analysis","volume":"78","author":"Franz","year":"2015","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurot.2026.e00926_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2021.581102","article-title":"Maintenance therapy with everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis - final results from the EMINENTS study","volume":"12","author":"Bobeff","year":"2021","journal-title":"Front Neurol"},{"issue":"6","key":"10.1016\/j.neurot.2026.e00926_bib24","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1212\/WNL.0b013e3182815428","article-title":"Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma","volume":"80","author":"Krueger","year":"2013","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00926_bib25","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1086\/316951","article-title":"Mutational analysis in a cohort of 224 tuberous sclerosis patients indicates increased severity of TSC2, compared with TSC1, disease in multiple organs","volume":"68","author":"Dabora","year":"2001","journal-title":"Am J Hum Genet"},{"issue":"10","key":"10.1016\/j.neurot.2026.e00926_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmg.2022.104573","article-title":"Genotype\/phenotype correlation in 123 Chinese patients with Tuberous sclerosis complex","volume":"65","author":"Ng","year":"2022","journal-title":"Eur J Med Genet"},{"issue":"1","key":"10.1016\/j.neurot.2026.e00926_bib27","doi-asserted-by":"crossref","first-page":"8","DOI":"10.5114\/fn.2015.49969","article-title":"Erk activation as a possible mechanism of transformation of subependymal nodule into subependymal giant cell astrocytoma","volume":"53","author":"Siedlecka","year":"2015","journal-title":"Folia Neuropathol"},{"issue":"12","key":"10.1016\/j.neurot.2026.e00926_bib28","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1093\/jnen\/63.12.1236","article-title":"Pathogenesis of tuberous sclerosis subependymal giant cell astrocytomas: biallelic inactivation of TSC1 or TSC2 leads to mTOR activation","volume":"63","author":"Chan","year":"2004","journal-title":"J Neuropathol Exp Neurol"},{"issue":"2","key":"10.1016\/j.neurot.2026.e00926_bib29","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1177\/08830738040190020401","article-title":"Tuberin and hamartin expression is reduced in the majority of subependymal giant cell astrocytomas in Tuberous sclerosis complex consistent with a two-hit model of pathogenesis","volume":"19","author":"Jozwiak","year":"2004","journal-title":"J Child Neurol"},{"issue":"56","key":"10.1016\/j.neurot.2026.e00926_bib30","doi-asserted-by":"crossref","first-page":"95516","DOI":"10.18632\/oncotarget.20764","article-title":"Subependymal giant cell astrocytomas in Tuberous sclerosis complex have consistent TSC1\/TSC2 biallelic inactivation, and no BRAF mutations","volume":"8","author":"Bongaarts","year":"2017","journal-title":"Oncotarget"}],"container-title":["Neurotherapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000966?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1878747926000966?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T11:16:52Z","timestamp":1783163812000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1878747926000966"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S1878747926000966"],"URL":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00926","relation":{},"ISSN":["1878-7479"],"issn-type":[{"value":"1878-7479","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genotype and subependymal lesion burden influence volumetric response to everolimus in tuberous sclerosis complex-associated subependymal giant cell astrocytoma: A 10-year real-world study","name":"articletitle","label":"Article Title"},{"value":"Neurotherapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurot.2026.e00926","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc. on behalf of American Society for Experimental NeuroTherapeutics.","name":"copyright","label":"Copyright"}],"article-number":"e00926"}}